Caryn Peterson

CIK: 0001857256

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)16 (57.1%)

Compensation grants

Other (G, F, J, C, D, …)12 (42.9%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ASPE

Aspen Neuroscience, Inc.

Director

GOSS

Gossamer Bio, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (28 total)

GOSS
Gossamer Bio, Inc.
Aug 24, 2026
Award(A)
Stock Option (Right to Buy)
Direct
5.8M shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
32.3K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
18.8K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
22.8K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
9.2K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
506.3K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
440K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
375K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
125K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
157.5K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
157.5K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
126.7K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
21.2K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
18.8K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
22.8K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
9.2K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
32.3K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
506.3K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
440K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
375K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
125K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
157.5K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
157.5K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
126.7K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
21.2K shares-

		Type	Shares	Price		Ownership
Aug 24, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	5,800,051	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	32,334	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	18,834	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	22,784	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	9,167	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	506,250	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	440,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	375,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	125,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	157,500	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	157,500	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	126,667	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	21,167	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	18,834	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	22,784	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	9,167	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	32,334	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	506,250	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	440,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	375,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	125,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	157,500	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	157,500	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	126,667	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	21,167	-	-	Direct

1-25 of 28 transactions

About Peterson Caryn

Peterson Caryn (SEC CIK 0001857256) files insider reports with the SEC as Director of Aspen Neuroscience, Inc. (ASPE) and Chief Development Officer of Gossamer Bio, Inc. (GOSS).

Signal8 holds 6 ownership filings by Peterson Caryn (1 Form 3, 5 Form 4), filed between Mar 6, 2025 and Oct 29, 2026. Those filings report 28 transactions, from Mar 4, 2025 to Aug 24, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Peterson Caryn's filings is in SAN DIEGO, CA.

Recent filings by Peterson Caryn

Aug 24, 2026: Grant or award of GOSS derivative securities (Form 4, code A).
Mar 19, 2026: Grants or awards of GOSS derivative securities (4 lines, Form 4, code A).
Mar 19, 2026: Disposition to issuer transactions of GOSS derivative securities (12 lines, Form 4, code D).
Mar 19, 2026: Grants or awards of GOSS derivative securities (8 lines, Form 4, code A).

Other insiders filing for Aspen Neuroscience, Inc. (ASPE)

ARCH Venture Fund X, L.P., 10% Owner
ARCH Venture Partners XIV, L.P., 10% Owner
Spaventa Andrew, Director
Hasnain Faheem, Executive Chair
ORBIMED ADVISORS LLC, Director
Boerneke Jeffrey Lee, General Counsel and Secretary

How to read Form 4 transaction codes